Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | PHASE1 | COMPLETED | 198 | — | — | May 1, 2019 | Feb 15, 2024 | Jul 5, 2024 | 18 | United States |
Safety and tolerability
| Arm | Type | Description |
|---|---|---|
| XmAb®23104 Monotherapy | EXPERIMENTAL | XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles |
| XmAb®23104 Combination Therapy with Ipilimumab | EXPERIMENTAL | XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab) |
| Name | Type | Description |
|---|---|---|
| XmAb®23104 | BIOLOGICAL | Monoclonal bispecific antibody |
| Yervoy® (ipilimumab) | BIOLOGICAL | Monoclonal antibody |
Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following: 1. Melanoma (excluding uveal melanoma) 2. Cervical carcinoma 3. Pancreatic carcinoma 4...